文献速递核素与放射性配体治疗

[177Lu]Lu-萨妥肽四氮杂环十二烷在生长抑素受体阳性神经内分泌肿瘤中的作用

The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2025-08-11

本文综述[177Lu]Lu-satoreotide tetraxetan(一种生长抑素受体拮抗剂)治疗神经内分泌肿瘤的临床前与临床疗效和安全性数据,并简要概述其他在研SSTR拮抗剂。

要点

  • SSTR拮抗剂不内化但可结合更多受体位点并延长肿瘤滞留。
  • [177Lu]Lu-satoreotide tetraxetan是研究最广泛的SSTR拮抗剂。
  • 临床前与临床证据支持SSTR拮抗剂的治疗效用。

核心结论

  • 不断积累的临床前和临床证据支持SSTR拮抗剂的治疗效用。
  • [177Lu]Lu-satoreotide tetraxetan是迄今研究最广泛的SSTR拮抗剂。

研究设计与样本

  • 综述,评估[177Lu]Lu-satoreotide tetraxetan治疗神经内分泌肿瘤的临床前和临床数据。

主要发现

  • SSTR拮抗剂与受体结合但不发生显著内化。
  • SSTR拮抗剂可结合更多受体位点并 exhibit 延长肿瘤滞留。
  • 这些特性可能增强成像灵敏度和治疗疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor with receptor agonists has emerged as a key treatment in the management of well-differentiated neuroendocrine tumors (NETs). The therapeutic efficacy of these agents has traditionally been attributed to receptor-mediated internalization of the radiolabeled peptide into tumor cells. In contrast, somatostatin receptor (SSTR) antagonists bind to the receptor without undergoing significant internalization. Despite this theoretical limitation, accumulating preclinical and clinical evidence supports the therapeutic utility of SSTR antagonists. These agents have been shown to bind to a greater number of receptor sites and exhibit prolonged tumor retention, properties that may enhance both imaging sensitivity and therapeutic efficacy. Among the antagonists studied, [¹⁷⁷Lu]Lu-satoreotide tetraxetan is the most extensively investigated to date. In this article, we review both preclinical and clinical data evaluating the efficacy and safety of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in the treatment of neuroendocrine tumors. We also provide a brief overview of other SSTR antagonists currently under investigation.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shekhda KM, Navalkissoor S. The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors. Semin Nucl Med. 2025. PMID: 40796453. doi:10.1053/j.semnuclmed.2025.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。